36 results about "T-Cell Specificity" patented technology

A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123. In some embodiments, such a CD123 chimeric antigen receptor (CD123CAR) gene includes an anti-CD123 scFv region fused in frame to a modified IgG4 hinge region comprising an S228P substitution, an L235E substitution, and optionally an N297Q substitution; a costimulatory signaling domain; and a T cell receptor (TCR) zeta chain signaling domain. When expressed in healthy donor T cells (CD4 / CD8), the CD123CARs redirect T cell specificity and mediated potent effector activity against CD123+ cell lines as well as primary AML patient samples. Further, T cells obtained from patients with active AML can be modified to express CD123CAR genes and are able to lyse autologous AML blasts in vitro. Finally, a single dose of 5.0 x 106 CAR123 T cells results in significantly delayed leukemic progression in mice. These results suggest that CD123CAR-transduced T cells may be used as an immunotherapy for the treatment of high risk AML.

The invention relates to a bispecific antibody and a preparation method and application thereof. The bispecific antibody contains a structural domain capable of being bound to CD20, a structural domain capable of being bound to CD3 and a heterogeneous dipolymer Fc region, and the structural domain capable of being bound to the CD20 and the structural domain capable of being bound to the CD3 are independently selected from an Fab region, an ScFv region or an sDab region. The bispecific antibody can stably and efficiently target the CD20 and the CD3, and can mediate T-cell specific killing tumorcells.

The invention provides a method of targeting T-cells to tumor cells using a tumor-associated antigen (TAA) specific antibody and a T-cell specific antibody, wherein the two antibodies can bind to each other through a high affinity avidin / biotin or streptavidin / biotin connection. The invention further provides methods to target activated T-cells to different tumor types by using a T-cell specific antibody that is specific to an activated T-cell surface molecule like CTLA-4.

The invention relates to a polypeptide mixture for interfering the formation of MHC (Major Histocompability Complex)-pathogenic peptide-TCR (Cell Antigen Receptor) regardless of the genetic background of patients. The formation of MHC-pathogenic peptide-TCR is interfered by the following steps of: interfering the combination of pathogenic peptide and MHC and the combination of pMHC and the specific TCR; inhibiting the formation of immunological synapse generated by a specific T-cell immunoreaction; inhibiting the number and the density of MHC-specific immunoreaction mediated pathogenic peptide-TCR in the immunological synapse; and inhibiting the transmission of an intense activation signal in the immunological synapse and negatively adjusting the ongoing intense specific immunoreaction mediated by the T-cell; weakening the activation, multiplication and effect capabilities of specific immunocyte so that extreme T-cell specific immunoreaction becomes milder and durable. The invention is used for treating diseases accompanied by the extreme T-cell specific immunoreaction, such as serious flu, SARS (Severe Acute Respiratory Syndrome), hand-foot-and-mouth diseases, viral pneumonia, bacterial infection, serious self immune diseases, and the like.

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.